The penetration of cefoxitin into cerebrospinal fluid (CSF) was studied in 25 patients with purulent meningitis treated with antibiotics other than cefoxitin. Each patient received three 2-g doses of cefoxitin at 6-h intervals. Blood and CSF samples were obtained before and at 2, 4, or 6 h after the first and third doses. CSF cefoxitin concentrations were found in all patients and varied between 1.2 and 22.0 ,tg/ml, with a majority of the concentrations falling within a range from 1.2 to 6.2 ,ug/ml. The concentrations tended to be higher in CSF samples drawn after the third cefoxitin dose than in those drawn after the first cefoxitin dose, indicating an accumulation of cefoxitin in CSF with repeated doses. Peak cefoxitin concentrations in CSF seemed to occur between 2 and 6 h after intravenous administration of the drug since the highest concentrations were found in patients from whom CSF samples were taken 4 h after the doses. In patients with bacterial meningitis, it should be possible to achieve therapeutic cefoxitin levels in CSF by using nontoxic doses of the antibiotic.
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Cefoxitin has been found to give concentrations in cerebrospinal fluid (CSF) which are similar to those obtained with ampicillin both in individuals with and in individuals without meningeal inflammation (3, 5) . It has been used therapeutically in very few patients with meningitis, and published data (5) of two patients with gram-negative meningitis do not allow the conclusion that cefoxitin is effective in the treatment of meningitis since both of these patients also received other antibiotics. However, since cefoxitin has a very broad antibacterial spectrum, cases of bacterial meningitis caused by pathogens which are resistant to most other antibiotics but susceptible to cefoxitin are likely to appear. The present study was undertaken to evaluate the CSF penetration of cefoxitin in patients with bacterial meningitis treated with other antibiotics.
MATERIALS AND METHODS
Pa,tients. Twenty-five patients with bacterial meningitis were included in the study. They were all admitted to one hospital in Sao Paolo. The mean age was 32 years (range, 19 to 67 years). Five patients were females, and 20 were males. Upon admission, all patients had clinical signs of meningitis with headache, fever, and nuchal rigidity. Two patients were unconscious. The mean duration of symptoms upon admis- 48 h, when the bacterial etiology was known, treatment was changed to other antibiotics in some patients. In addition to the above antibiotics, all patients received three doses of cefoxitin (Mefoxin; Merck Sharp & Dohme, Rahway, N.J.) administered as intravenous bolus injections over 3 to 5 min at 6-h intervals. These doses were administered concurrently with the first three doses of ampicillin or benzylpenicillin.
Assays of cefoxitin concentrations. Cefoxitin concentrations in serum and CSF were studied in samples drawn before the first cefoxitin dose and at 2, 4, or 6 h after the first and third cefoxitin doses. The patients were randomly allocated to the three sampling times by using an allocation list. For cefoxitin assays, a paper disk diffusion technique was used. Brain heart infusion agar was inoculated with a strain of Staphylococcus aureus (MB 2786; Merck Sharp & When the CSF concentrations achieved after the third cefoxitin dose were compared with those obtained after the first dose, 16 patients had higher absolute concentrations and 15 had higher concentrations in relation to concurrent serum levels in the sample taken after the third dose. By the Student t test for paired differences, this difference was significant (P < 0.05) both in the total material and in the group of patients sampled at 2 h after cefoxitin administration. Due to pronounced individual variations, it was difficult to compare the CSF concentrations obtained after 2, 4, and 6 h in the three groups of patients. However, a tendency toward higher concentrations at 4 and 6 h was noted. This difference was not statistically significant if the absolute CSF concentrations were compared, but the concentrations in relation to concurrent serum concentrations were significantly (P < 0.01) higher at 4 and 6 h than those at 2 h after the first cefoxitin doses and also higher at 6 h than at 2 h after the third cefoxitin doses (t test of the mean). These results indicated that the peak CSF concentration of cefoxitin occurred from 2 to 6 h after intravenous administration of the drug.
All patients were followed for adverse reactions to cefoxitin, the only reported one being a pain reaction at the infusion site in one patient. Two of the patients with pneumococcal meningitis died of their infections, and the deaths were considered definitely not related to the cefoxitin administration. Since cefoxitin was not used therapeutically, no evaluation was made of the outcome of the treatment.
DISCUSSION
The increasing frequency of antibiotic resistance among bacterial species causing meningitis, e.g., Haemophilus influenzae (2, 9), has created a need for new antibiotics which can be used for the treatment of purulent meningitis. Cefoxitin, a cephamycin for parenteral use, has an antibacterial spectrum which is broad and which covers most bacterial species causing meningitis, including Escherichia coli, Klebsiella, Proteus spp. and beta-lactamase-producing strains of Haemophilus influenzae (8) . However, the miniimum inhibitory concentrations of cefoxitin for these pathogens are in the range of 0.5 to 8 ,ug/ml, and a prerequisite for the use of cefoxitin therapeutically would be that the antibiotic have a good penetrability over the blood-CSF barrier. (5) in patients with meningitis. The pharmacokinetics of the CSF penetration seemed to be characterized by a peak concentration at between 2 and 6 h after the administration of the 2-g doses. The concentrations obtained after the third dose tended to be higher, both absolutely and relatively to the concurrent serum concentrations, than those obtained after the first cefoxitin dose, indicating an accumulation in CSF of cefoxitin with repeated doses. Our results, in combination with those of others, indicate that cefoxitin has a good penetrability into CSF ofpatients with bacterial meningitis and that it might be considered in selected cases of purulent meningitis when the susceptibility pattern indicates its usefulness. However, the 2-g, 6-h regimen used by us is probably too low of a dose to attain CSF concentrations of cefoxitin which are well above the minimum inhibitory concentrations for bacteria classified as susceptible to cefoxitin; therefore, daily doses of 12 to 18 g of cefoxitin will probably be required in the therapeutic situation. These doses are somewhat higher than those recommended by the manufacturers of cefoxitin, but should impose no risks of serious adverse reactions since cefoxitin seems to have a high degree of safety (7) .
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